인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록·키워드
Acute Myeloid Leukemia (AML) affects nearly 500,000 individuals annually, making it a prominent avenue of study. About 30% of patients express a genetic insertion mutation within the FLT3 receptor (known as FLT3-ITD) responsible for regulating the hematopoietic process of these cells, worsening patient prognosis. Whether this is caused by the overactive FLT3 or specifically the JAK2/STAT5 pathway activated by FLT3 is unknown, making both FLT3 and JAK2 inhibition important options to consider. Current treatments of FLT3-mutated AML include FLT3 inhibitors but are not specific to FLT3 and act as broad-spectrum tyrosine kinase inhibitors. A newly developed, highly specific FLT3-ITD inhibitor (known as FLT3-IN-3) may provide new treatment options. Another drug, known as BMS 911543, is a potent JAK2 inhibitor and may lead to similar or improved results compared to a specific FLT3 inhibitor by allowing other pathways within the FLT3 signaling cascade to continue without the increase in cellular proliferation from the JAK2/STAT5 pathway. With further investigation into the FLT3/JAK2/STAT5 pathway, and based on previous research, Vitamin A may be a novel treatment option in combination with one of these inhibitors as it also acts through a JAK2 signaling cascade. Vitamin A is currently used as a therapeutic agent for the treatment of Acute Promyelocytic Leukemia and has been shown to cause cellular differentiation, but its effects have not been explored in AML. The objective of this study is to utilize three human AML cell lines (MV4-11, PL-21, and NB-4) that range in FLT3-ITD expression to investigate the half-maximal inhibitory concentrations (IC50) of FLT3-IN-3 and BMS 911543, and the effects of these inhibitors and physiological concentrations of Vitamin A to elicit cellular differentiation and apoptosis. Methods include measuring cell death and viability using a hemocytometer and analysis of surface expression of various markers of cellular processes by flow cytometry. Current results have revealed Vitamin A to be potentially cytotoxic to the MV4-11 cell line by inducing apoptosis and a potential differentiation agent in the PL-21 cell line. Ranges of IC50 for both inhibitors have been experimentally determined to be between 12 and 14 nM for FLT3-IN-3 and between 4 and 5 uM for BMS 911543. Utilizing these concentrations, experiments to determine their effects on differentiation and apoptosis will be further investigated. Following completion, these results will allow AML cells to be treated with combinations of Vitamin A and each inhibitor to explore the effectiveness of combination therapy to best treat FLT3-mutated AML cancer patients.
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
최근 본 자료 전체보기
